Immediate Impact

4 standout
Sub-graph 1 of 2

Citing Papers

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 Standout
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
2023 Standout
2 intermediate papers

Works of Lenie Denteneer being referenced

Benefits and Disadvantages of Electronic Patient-reported Outcome Measures: Systematic Review
2020

Author Peers

Author Last Decade Papers Cites
Lenie Denteneer 102 49 46 50 11 266
Elena Tseli 154 46 32 28 12 320
Ariana Vora 42 54 24 84 11 328
Takayuki Sawada 173 43 69 14 12 295
Sophie Alami 98 96 59 27 17 332
Norimasa Kikuchi 164 44 68 15 11 331
Nolwenn Poquet 164 47 30 31 8 300
Jhb Geertzen 152 40 54 21 8 313
Ian M. Fowler 140 88 67 27 9 292
Gerlienke E. Voerman 117 25 23 46 12 331
Sandrine Plouvier 181 25 48 14 21 305

All Works

Loading papers...

Rankless by CCL
2026